A phase I trial of ATOR-1015 for the treatment of metastatic cancer

Trial Profile

A phase I trial of ATOR-1015 for the treatment of metastatic cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs ATOR-1015 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 25 Jan 2018 According to an Alligator Biosciences media release, the company expects to complete the final clinical trial authorization ("CTA") enabling activities required for study initiation in H1 2018 and expects to commence the trial in the second half of 2018.
    • 25 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top